Insider Selling: uniQure (NASDAQ:QURE) CFO Sells 14,341 Shares of Stock

uniQure (NASDAQ:QURE) CFO Christian Klemt sold 14,341 shares of the company’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $153,448.70. Following the transaction, the chief financial officer now owns 152,372 shares of the company’s stock, valued at approximately $1,630,380.40. This represents a 8.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Christian Klemt also recently made the following trade(s):

• On Thursday, February 27th, Christian Klemt sold 2,916 shares of uniQure stock. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12.
• On Monday, December 9th, Christian Klemt sold 1,796 shares of uniQure stock. The stock was sold at an average price of $7.55, for a total transaction of $13,559.80.

uniQure Trading Up 8.9 %

Shares of QURE opened at $13.15 on Friday. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The company has a market cap of $640.73 million, a P/E ratio of -2.65 and a beta of 0.38. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The company’s fifty day simple moving average is $15.05 and its 200-day simple moving average is $9.79.

Institutional Investors Weigh In On uniQure

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC purchased a new stake in shares of uniQure in the fourth quarter valued at $38,410,000. Franklin Resources Inc. raised its stake in shares of uniQure by 33.1% in the fourth quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company’s stock valued at $35,103,000 after acquiring an additional 494,726 shares during the period. abrdn plc raised its stake in shares of uniQure by 381.7% in the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after acquiring an additional 1,528,581 shares during the period. Point72 Asset Management L.P. raised its stake in shares of uniQure by 81.3% in the fourth quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock valued at $31,282,000 after acquiring an additional 794,459 shares during the period. Finally, Integral Health Asset Management LLC raised its stake in shares of uniQure by 175.0% in the fourth quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock valued at $19,426,000 after acquiring an additional 700,000 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on QURE shares. Mizuho upped their target price on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 19th. HC Wainwright upped their target price on shares of uniQure from $25.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. StockNews.com upgraded shares of uniQure to a “sell” rating in a research report on Wednesday, February 5th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Finally, The Goldman Sachs Group upped their price target on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $38.89.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.